STOCK MARKET BSE NSE

Sun Pharma Expects Ranbaxy Business to be Profitable in Short Term

Published: 07th April 2014 12:03 PM  |   Last Updated: 07th April 2014 12:03 PM   |  A+A-

Sun Pharmaceutical Industries Ltd Managing Director Dilip Shanghvi said he expects Ranbaxy Laboratories Ltd to become profitable in the short term.

Sun said it will buy Ranbaxy in a $3.2 billion all-share deal, creating the world's fifth-largest generic drug maker from two firms struggling with quality issues in the lucrative United States market.

Sun plans to focus on remediation of compliance issues that have resulted in bans at multiple Ranbaxy plants, Shanghvi told analysts on a conference call.

Ranbaxy's underlying business has "robust growth," and profitability potential, based on which the price Sun is paying for the deal is "justified," Shanghvi said.

The managing director also said Sun would continue to look for acquisition opportunities even after the Ranbaxy acquisition.

Stay up to date on all the latest Business news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp